PTGDS
Prostaglandin-H2 D-isomerase
Also known as: L-PGDS, PGDS, PTGDS_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P41222
- Gene
- PTGDS
- Ensembl
- ENSG00000107317
- Chromosome
- 9
- Canonical length
- 190 aa
- Protein class
- Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
The protein encoded by this gene is a glutathione-independent prostaglandin D synthase that catalyzes the conversion of prostaglandin H2 (PGH2) to postaglandin D2 (PGD2). PGD2 functions as a neuromodulator as well as a trophic factor in the central nervous system. PGD2 is also involved in smooth muscle contraction/relaxation and is a potent inhibitor of platelet aggregation. This gene is preferentially expressed in brain. Studies with transgenic mice overexpressing this gene suggest that this gene may be also involved in the regulation of non-rapid eye movement sleep. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
190 residues, UniProt reviewed canonical sequence.
>P41222|PTGDS
1 MATHHTLWMG LALLGVLGDL QAAPEAQVSV QPNFQQDKFL GRWFSAGLAS NSSWLREKKA
61 ALSMCKSVVA PATDGGLNLT STFLRKNQCE TRTMLLQPAG SLGSYSYRSP HWGSTYSVSV
121 VETDYDQYAL LYSQGSKGPG EDFRMATLYS RTQTPRAELK EKFTAFCKAQ GFTEDTIVFL
181 PQTDKCMTEQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PTGDS can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.35
- Highest tissue expression
- 4,605 nTPM
Expression across tissuesHPA
Tissue
- heart muscle: 4,605 nTPM
- spinal cord: 3,338 nTPM
- midbrain: 3,250 nTPM
- testis: 3,126 nTPM
- basal ganglia: 2,972 nTPM
- amygdala: 2,493 nTPM
Single-cell type
- peritubular myoid cells: 43,552 nCPM
- leydig cells: 23,234 nCPM
- retinal pigment epithelial cells: 8,854 nCPM
- epididymal principal cells: 6,097 nCPM
- epididymal efferent duct absorptive cells: 4,754 nCPM
- decidual stromal cells: 4,382 nCPM
Immune cell
- plasmacytoid DC: 1,390 nTPM
- gdT-cell: 51 nTPM
- total PBMC: 11 nTPM
- naive CD8 T-cell: 9.9 nTPM
- memory CD8 T-cell: 6.3 nTPM
- memory CD4 T-cell: 4.3 nTPM
Brain region
- white matter: 3,261 nTPM
- cerebellum: 3,086 nTPM
- basal ganglia: 2,995 nTPM
- medulla oblongata: 2,947 nTPM
- thalamus: 2,682 nTPM
- midbrain: 2,622 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.85
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 0.53
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cyclooxygenase pathway
- gene expression
- mast cell degranulation
- negative regulation of male germ cell proliferation
- prostaglandin biosynthetic process
- prostanoid biosynthetic process
- regulation of circadian sleep/wake cycle, sleep
- response to glucocorticoid
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PTGDS as an antibody target. Whether an autoantibody or antibody against PTGDS could matter depends on whether native PTGDS is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PTGDS is annotated as secreted, so native PTGDS circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PTGDS as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...